Sort
64,565 grants matching “drug discovery”
Marfan Aortic Embryologic Origin Influences Aneurysm Formation
$654,599Michael Peter Fischbein · Stanford University · R01 · FY2022 · HL
Marfan Aortic Embryologic Origin Influences Aneurysm Formation
$654,599Michael Peter Fischbein · Stanford University · R01 · FY2023 · HL
EBV NUCLEAR PROTEINS IN B CELL GROWTH TRANSFORMATION
$654,566Brigham And Women'S Hospital · R01 · FY2002 · CA
Roles for SGK1 in Cardiometabolic Heart Failure with Preserved Ejection Fraction
$654,530Erik Blackwood · Utah State Higher Education System--University Of Utah · R01 · FY2025 · HL
Identification of therapeutic targets for leukemia stem cells in AML-iPSC models
$654,506Eirini Papapetrou · Icahn School Of Medicine At Mount Sinai · R01 · FY2021 · CA
YEAST CHEMICAL GENOMICS IS A POWERFUL TOOL THAT IS BEING APPLIED TO DRUG DISCOVERY. THIS APPROACH ALLOWS THE STUDY OF COMPOUND-TARGET RELATIONSHIPS
$654,504Institute For Medical Research Inc · · FY2014 · National Aeronautics and Space Administration
Discovery and development of novel anti-HCMV agents targeting the UL89 terminase protein
$654,500Robert James Geraghty · University Of Minnesota · R01 · FY2022 · AI
Discovery and development of novel anti-HCMV agents targeting the UL89 terminase protein
$654,500Robert James Geraghty · University Of Minnesota · R01 · FY2020 · AI
Discovery and development of novel anti-HCMV agents targeting the UL89 terminase protein
$654,500Robert James Geraghty · University Of Minnesota · R01 · FY2023 · AI
Discovery and development of novel anti-HCMV agents targeting the UL89 terminase protein
$654,500Robert James Geraghty · University Of Minnesota · R01 · FY2019 · AI
Discovery and development of novel anti-HCMV agents targeting the UL89 terminase protein
$654,500Robert James Geraghty · University Of Minnesota · R01 · FY2021 · AI
Rational design and synthesis of small molecule inhibitors targeting unique pathogenic mechanisms in Gram- and Gram+ bacteria important in UTI
$654,484James W Janetka · Washington University · U19 · FY2024 · AI
Diacylglycerol kinase in airway smooth muscle functions
$654,449Deepak A Deshpande · Thomas Jefferson University · R01 · FY2024 · HL
Th17-mediated immunity to fungal infections
$654,426Sarah L. Gaffen · University Of Pittsburgh At Pittsburgh · R56 · FY2010 · AI
Evaluating the therapeutic potential of hypoxia mimetics in inflammatory demyelinating disease
$654,426D. Richard Milner · San Diego Biomedical Research Institute · R01 · FY2025 · NS
Research and cloud deployment of enhanced sampling methods in MovableType
$654,406Lance M Westerhoff · Quantumbio, Inc. · R44 · FY2025 · GM
Research and cloud deployment of enhanced sampling methods in MovableType
$654,406Lance M Westerhoff · Quantumbio, Inc. · R44 · FY2024 · GM
Structure-based Bioengineering of Wnt Surrogates for Intestinal Stem Cell Biology and Therapy
$654,389Calvin J Kuo · Stanford University · R01 · FY2022 · DK
Operations and clinical assesment core
$654,362William T Carpenter · University Of Maryland Baltimore · P50 · FY2009 · MH
Coupling Epitranscriptomics to Molecular Disease Mechanisms and Nucleic Acid Therapeutics in Persistent Residual HIV Infection
$654,356Keith Thomas Gagnon · Southern Illinois University Carbondale · R61 · FY2022 · AI
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias
$654,354Jian Jin · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA
Hemopexin as an Early Biomarker of Anthracycline Cardiac Toxicity
$654,307Aarti Asnani · Beth Israel Deaconess Medical Center · R01 · FY2023 · HL
Accurate protein folding software to predict ligand-induced conformational changes in G protein-coupled receptors
$654,257Steven Joseph Darnell · Dnastar, Inc. · R44 · FY2016 · GM
NEUROPHYSIOLOGICAL BIOMARKERS IN PRECLINICAL ASSAYS OF SUSTAINED ATTENTION
$654,255Gregory V Carr · Lieber Institute, Inc. · R56 · FY2021 · MH
SureFection Technology for High-Throughput Primary Cell Transfection
$654,082Yong Huang · Rational Biotechnology, Inc. · R44 · FY2009 · RR